Overview of Subsequent Entry Biologics for the Management of Inflammatory Bowel Disease and Canadian Association of Gastroenterology Position Statement on Subsequent Entry Biologic... by Shane M Devlin, Brian Bressler, Charles N Bernstein, Richard N Fedorak, Alain Bitton, Harminder Singh, Brian G Feagan

Get full text

Therapeutic Drug Monitoring for Dose Optimization of Infliximab in Patients With Inflammatory Bowel Disease: An Analysis of Canadian Real-World Data by David C. Sealey, Kai Fai Ho, Z. Christina Zhou, Michael Clark, Brian G. Feagan, Remo Panaccione, A. Hillary Steinhart, Elena Bolshtyansky, Martin Williamson, Waqqas Afif

Get full text

Use of external control arms in immune-mediated inflammatory diseases: a systematic review by Brian G Feagan, Vipul Jairath, Claire E Parker, Christopher Ma, Siddharth Singh, John K MacDonald, Joshua Chang, Alexa Zayadi, Robert Edge, Blue Neustifter, Guowei Zhong

Get full text

Effect of Risankizumab Induction and Maintenance Therapy on the Rate of Hospitalization in Patients with Crohn’s Disease by Brian G. Feagan, Remo Panaccione, Stefan Schreiber, Edward V. Loftus, Jr., Laurent Peyrin-Biroulet, Takehiro Arai, Wan-Ju Lee, Jenny Griffith, Jasmina Kalabic, Kristina Kligys, Si Xuan, Xiaomei Liao, Marc Ferrante

Get full text

Recommendations for standardizing biopsy acquisition and histological assessment of immune checkpoint inhibitor-associated colitis by Brian G Feagan, Vipul Jairath, Reetesh K Pai, Rish K Pai, Amitabh Srivastava, Christopher Ma, Christophe Rosty, David F Schaeffer, Roger M Feakins, Gregory Y Lauwers, Jonathan Krell, Richard Kirsch, Leonardo Guizzetti, John K MacDonald, Won-Tak Choi, Stefanie C McFarlane, Joanna C. Walsh

Get full text